Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 1.06
CRME's Cash to Debt is ranked higher than
55% of the 1428 Companies
in the Global Biotechnology industry.

( Industry Median: 39.38 vs. CRME: 1.06 )
CRME' s 10-Year Cash to Debt Range
Min: 1.06   Max: No Debt
Current: 1.06

Equity to Asset 0.34
CRME's Equity to Asset is ranked higher than
55% of the 1094 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. CRME: 0.34 )
CRME' s 10-Year Equity to Asset Range
Min: 0.18   Max: 0.98
Current: 0.34

0.18
0.98
F-Score: 2
Z-Score: -6.15
M-Score: 2.15
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating margin (%) -55.58
CRME's Operating margin (%) is ranked higher than
75% of the 1159 Companies
in the Global Biotechnology industry.

( Industry Median: -96.70 vs. CRME: -55.58 )
CRME' s 10-Year Operating margin (%) Range
Min: -12543.75   Max: 55.51
Current: -55.58

-12543.75
55.51
Net-margin (%) -61.00
CRME's Net-margin (%) is ranked higher than
74% of the 1159 Companies
in the Global Biotechnology industry.

( Industry Median: -75.86 vs. CRME: -61.00 )
CRME' s 10-Year Net-margin (%) Range
Min: -12075   Max: 105.81
Current: -61

-12075
105.81
ROE (%) -74.87
CRME's ROE (%) is ranked higher than
59% of the 1311 Companies
in the Global Biotechnology industry.

( Industry Median: -30.34 vs. CRME: -74.87 )
CRME' s 10-Year ROE (%) Range
Min: -127.24   Max: 116.12
Current: -74.87

-127.24
116.12
ROA (%) -37.08
CRME's ROA (%) is ranked higher than
66% of the 1436 Companies
in the Global Biotechnology industry.

( Industry Median: -25.14 vs. CRME: -37.08 )
CRME' s 10-Year ROA (%) Range
Min: -101.57   Max: 51.35
Current: -37.08

-101.57
51.35
ROC (Joel Greenblatt) (%) -383.60
CRME's ROC (Joel Greenblatt) (%) is ranked higher than
72% of the 1397 Companies
in the Global Biotechnology industry.

( Industry Median: -359.85 vs. CRME: -383.60 )
CRME' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -4604.34   Max: 1516.93
Current: -383.6

-4604.34
1516.93
Revenue Growth (3Y)(%) 154.00
CRME's Revenue Growth (3Y)(%) is ranked higher than
99% of the 775 Companies
in the Global Biotechnology industry.

( Industry Median: 2.20 vs. CRME: 154.00 )
CRME' s 10-Year Revenue Growth (3Y)(%) Range
Min: -75.5   Max: 205.2
Current: 154

-75.5
205.2
EBITDA Growth (3Y)(%) -20.60
CRME's EBITDA Growth (3Y)(%) is ranked higher than
64% of the 821 Companies
in the Global Biotechnology industry.

( Industry Median: -2.60 vs. CRME: -20.60 )
CRME' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -47.5   Max: 27
Current: -20.6

-47.5
27
EPS Growth (3Y)(%) -17.90
CRME's EPS Growth (3Y)(%) is ranked higher than
68% of the 803 Companies
in the Global Biotechnology industry.

( Industry Median: -5.30 vs. CRME: -17.90 )
CRME' s 10-Year EPS Growth (3Y)(%) Range
Min: -48.7   Max: 24.2
Current: -17.9

-48.7
24.2
» CRME's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

CRME Guru Trades in Q1 2014

Jim Simons 220,613 sh (+0.78%)
» More
Q2 2014

CRME Guru Trades in Q2 2014

Jim Simons 143,298 sh (-35.05%)
» More
Q3 2014

CRME Guru Trades in Q3 2014

Jim Simons 84,113 sh (-41.30%)
» More
Q4 2014

CRME Guru Trades in Q4 2014

Jim Simons 77,113 sh (-8.32%)
» More
» Details

Insider Trades

Latest Guru Trades with CRME

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 312.50
CRME's Forward P/E is ranked higher than
82% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. CRME: 312.50 )
N/A
P/B 9.48
CRME's P/B is ranked higher than
52% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 7.01 vs. CRME: 9.48 )
CRME' s 10-Year P/B Range
Min: 1.02   Max: 33.82
Current: 9.48

1.02
33.82
P/S 5.52
CRME's P/S is ranked higher than
85% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 36.81 vs. CRME: 5.52 )
CRME' s 10-Year P/S Range
Min: 3.26   Max: 305.91
Current: 5.52

3.26
305.91
EV-to-EBIT -10.30
CRME's EV-to-EBIT is ranked higher than
79% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. CRME: -10.30 )
CRME' s 10-Year EV-to-EBIT Range
Min: -18.9   Max: 97.8
Current: -10.3

-18.9
97.8
Current Ratio 1.76
CRME's Current Ratio is ranked higher than
57% of the 1412 Companies
in the Global Biotechnology industry.

( Industry Median: 4.33 vs. CRME: 1.76 )
CRME' s 10-Year Current Ratio Range
Min: 1.14   Max: 36.6
Current: 1.76

1.14
36.6
Quick Ratio 1.47
CRME's Quick Ratio is ranked higher than
57% of the 1412 Companies
in the Global Biotechnology industry.

( Industry Median: 4.22 vs. CRME: 1.47 )
CRME' s 10-Year Quick Ratio Range
Min: 1.14   Max: 36.6
Current: 1.47

1.14
36.6
Days Inventory 225.15
CRME's Days Inventory is ranked higher than
81% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. CRME: 225.15 )
CRME' s 10-Year Days Inventory Range
Min: 207.85   Max: 1286.27
Current: 225.15

207.85
1286.27
Days Sales Outstanding 119.84
CRME's Days Sales Outstanding is ranked higher than
73% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 134.01 vs. CRME: 119.84 )
CRME' s 10-Year Days Sales Outstanding Range
Min: 4.04   Max: 2418.13
Current: 119.84

4.04
2418.13

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 227.60
CRME's Price/Tangible Book is ranked lower than
64% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 10.90 vs. CRME: 227.60 )
CRME' s 10-Year Price/Tangible Book Range
Min: 1.11   Max: 69.88
Current: 227.6

1.11
69.88
Price/Median PS Value 0.22
CRME's Price/Median PS Value is ranked higher than
99% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 3.10 vs. CRME: 0.22 )
CRME' s 10-Year Price/Median PS Value Range
Min: 0.21   Max: 40.8
Current: 0.22

0.21
40.8
Earnings Yield (Greenblatt) -9.70
CRME's Earnings Yield (Greenblatt) is ranked higher than
57% of the 1389 Companies
in the Global Biotechnology industry.

( Industry Median: -5.30 vs. CRME: -9.70 )
CRME' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1   Max: 19310.8
Current: -9.7

1
19310.8

Business Description

Industry: Biotechnology » Biotechnology
Compare:GSK, JNJ, PFE, RHHBY, NVS » details
Traded in other countries:COM.Canada, CKO1.Germany,
Cardiome Pharma Corp was incorporated on December 12, 1986. The Company is a specialty pharmaceutical company engaged in the development and commercialization of cardiovascular therapies that will improve the quality of life and health of patients suffering from heart disease. It currently has two marketed, in-hospital, cardiology products, BRINAVESS, for the rapid conversion of recent onset atrial fibrillation to sinus rhythm in adultsand and AGGRASTAT, a reversible GP IIb/IIIa inhibitor for use in Acute Coronary Syndrome patients. Both of its products are commercially available in numerous markets outside of the United States. BRINAVESS was approved in September 2010 and has been launched in the European Union, Iceland and Norway.
» More Articles for CRME

Headlines

Articles On GuruFocus.com
Julian Robertson’s "smart idea, grounded on exhaustive research, followed by a big bet" Jun 24 2011 
Julian Robertson’s Tiger Management Q1 Portfolio Update May 16 2011 
Julian Robertson Keeps Buying CRME, Selling AAPL Apr 13 2011 
More Word of Wisdom from Julian Robertson; Top 2Q10 Purchases: GOOG, EBAY, AAPL, CRME, GS Nov 04 2010 

More From Other Websites
Nasdaq stocks posting largest volume increases Apr 24 2015
Cardiome Receives BRINAVESS Reimbursement Approval From Belgian Authorities Apr 09 2015
Cardiome Receives BRINAVESS Reimbursement Approval From Belgian Authorities Apr 09 2015
Cardiome Receives BRINAVESS Reimbursement Approval From Belgian Authorities Apr 09 2015
CARDIOME PHARMA CORP Financials Apr 02 2015
Cardiome reports fourth quarter and full year 2014 financial results Mar 12 2015
Cardiome reports fourth quarter and full year 2014 financial results Mar 12 2015
Cardiome reports fourth quarter and full year 2014 financial results Mar 12 2015
Cardiome to hold fourth quarter and full year 2014 financial results conference call on March 12 Mar 05 2015
Cardiome to Hold Fourth Quarter and Full Year 2014 Financial Results Conference Call on March 12 Mar 05 2015
Cardiome to Hold Fourth Quarter and Full Year 2014 Financial Results Conference Call on March 12 Mar 05 2015
Cardiome Pharma (CRME) in Focus: Stock Rises 5.1% - Tale of the Tape Jan 15 2015
Cardiome Enters Development And Commercialization Agreement With Eddingpharm For BrinavessTM In... Dec 19 2014
Cardiome Enters Development and Commercialization Agreement with Eddingpharm for BRINAVESS™ in... Dec 19 2014
Mid-Afternoon Market Update: Lions Gate Shares Climb on Report of Dalian Wanda Stake; Crude Oil... Dec 01 2014
Mid-Day Market Update: ON Semiconductor Surges On $1 Billion Buyback Plan; POZEN Shares Slip Dec 01 2014
Mid-Morning Market Update: Markets Open Lower; Weatherford To Sell Engineered Chemistry, Drilling... Dec 01 2014
Cardiome Enters Commercialization Agreement With Aspen For Brinavess In South Africa Nov 17 2014
Cardiome Enters Commercialization Agreement with Aspen for BRINAVESS® in South Africa Nov 17 2014
Cardiome Enters Commercialization Agreement with Aspen for BRINAVESS® in South Africa Nov 17 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK